Almost immediately after the COVID-19 pandemic began, the ruling class vigorously campaigned against any policies that might impede its ability to accumulate profits while fighting the virus.
Governments around the world quickly decided on vaccine-only strategies, abandoning other public health measures. This has now largely been replaced by a complete “deprivation policy,” making even vaccines difficult to obtain for those who initially had access to them in significant numbers.
In this Thursday, April 29, 2021 photo, Sherry Cross-Child, a Canadian resident of Standoff, Alberta, receives a COVID-19 vaccination at the Pegan Karway border crossing near Bab, Montenegro. receive. (AP Photo/Iris Samuels)
To justify this destructive action, information about the virus is withheld or misrepresented, and various pseudoscientific claims are made to downplay the seriousness of the disease. This has created a fertile environment for backward anti-vaccine concepts and conspiracy theories that are openly supported by some of the most insane sections of the ruling class.
One of the arguments most often cited by “anti-vaxxers” is that there are a small number of cases of people developing cardiovascular complications after vaccination, and a small number of them are tragically fatal to vaccine recipients. caused death. They believe that the potential for these complications justifies refusing the vaccine, which is a serious disease that is well documented to have high mortality rates and long-term, life-altering consequences. claims to justify minimizing or denying the benefits of vaccines in preventing cancer. .
A study published in Nature Communications debunks this claim by analyzing the incidence of cardiovascular complications in a very large vaccinated population.
The study, led by the Universities of Cambridge, Bristol and Edinburgh, and supported by the British Heart Foundation (BHF) Data Science Center at Health Data Research UK, ran from 8 December 2020 to January 2020. Anonymised health records of 46 million UK adults were analyzed. 23rd, 2022.
Data scientists compared the incidence of cardiovascular disease after vaccination with the incidence before or without vaccination during the first two years of the vaccination program. They specifically evaluated the incidence of cardiovascular and thrombotic events after the first, second, and booster doses of COVID-19 vaccines from December 2020 to January 2022. Vaccines studied include mRNA vaccines (Pfizer’s BNT-162b2 and Moderna’s mRNA-1273). Adenovirus-based ChAdOx1 vaccine (AstraZeneca).
This study used Cox regression models to calculate adjusted hazard ratios (aHRs) comparing the risk of cardiovascular events after vaccination with the risk before or without vaccination. Across all doses and vaccine types, the incidence of thrombotic events (such as blood clots) was lower after vaccination, both arterial and venous events. The reduction was already evident after the first dose, with a 10% reduction in the risk of arterial thrombotic events after the first dose of the Pfizer vaccine.
An even greater reduction in cardiovascular events was observed after the second dose for all vaccine brands. For example, after the second dose of AstraZeneca’s ChAdOx1, the risk of arterial thrombotic events was reduced by 27%. The aHR for other diseases, such as pulmonary embolism and deep vein thrombosis, was also reduced.
A similar trend was observed with booster vaccinations, which helped keep event rates low compared to prevaccination levels. The study noted that the reduction in cardiovascular events was most pronounced in the weeks immediately following vaccination.
Both the mRNA vaccines (Pfizer and Moderna) and the adenovirus-based AstraZeneca vaccine showed reductions in arterial and venous events. However, the magnitude of risk reduction varied slightly by brand and dose, with mRNA vaccines showing slightly lower aHRs overall, especially after booster doses.
The reduction was still evident up to 24 weeks post-vaccination, but the magnitude of the reduction decreased over time.
Previous studies have found higher rates of rare cardiovascular complications after some COVID-19 vaccinations. This study confirms these findings, but importantly, no new adverse cardiovascular diseases were identified associated with COVID-19 vaccination, providing further reassurance that the benefits of vaccination outweigh the risks. This is what we offer.
These rare complications fall into two categories: vaccine-induced thrombotic thrombocytopenia (VITT) with the AstraZeneca vaccine, and myocarditis and pericarditis with the mRNA vaccines (Pfizer and Moderna).
VITT is a rare condition characterized by blood clots with a low platelet count. It can cause serious complications such as intracranial venous thrombosis (ICVT), which affects blood vessels in the brain. The study found that the incidence of VITT was higher than usual after the first dose of the AstraZeneca vaccine, with the highest risk occurring within the first two weeks after vaccination.
No increased risk of VITT was observed after the second dose of ChAdOx1 or after any dose of the mRNA vaccine, indicating that the risk was primarily associated with the first dose of the AstraZeneca vaccine.
Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the lining surrounding the heart. Both conditions can cause chest pain, fatigue, and other heart symptoms, but are often mild and resolve on their own. The increased risk of myocarditis and pericarditis was highest in the first week after vaccination for both the Pfizer and Moderna vaccines, and the risk generally returned to baseline levels within 4 weeks after vaccination.
Although rare complications have been associated with the COVID-19 vaccine, they were primarily associated with the first dose and generally occurred within the first few weeks after vaccination. The study highlights that although these risks exist, they are outweighed by the broader protective effects of vaccination against COVID-19 infection and related cardiovascular risks.
A major strength of this study is that a significant number of people were tested, which allowed researchers to evaluate vaccine efficacy across a variety of demographic and clinical subgroups, including age, gender, ethnicity, and previous health conditions. We were able to evaluate the effectiveness. Significant reductions in thrombotic events were observed in all subgroups, reinforcing the value of the vaccine in preventing COVID-19-related cardiovascular complications.
The vaccine was particularly effective in older people (over 40 years), with significantly lower risks of rare complications such as myocarditis, and the benefit in terms of reduced cardiovascular events was even more pronounced.
Co-lead author Dr Samantha Yip, a research fellow in the School of Public Health and Primary Care at the University of Cambridge, told Health Data Research UK: This program has been proven to provide protection from severe coronavirus disease (COVID-19) and save millions of lives around the world. ”
Professor William Whiteley, Deputy Director of the BHF Data Science Center and Professor of Neurology and Epidemiology at the University of Edinburgh, said the study found that ‘the benefits of second and booster vaccinations are likely to reduce the risk of post-vaccination complications such as heart attacks and strokes. “This shows that there are fewer cardiovascular events.” Vaccination outweighs very rare cardiovascular complications. ”
The results demonstrate the great potential of society’s creative and productive forces. But while vaccines are an important tool in the fight against the pandemic, they are not enough. Without policies to completely eliminate the virus through a comprehensive regime of testing, tracing and isolation, vaccination programs will be little more than palliative care.
This can now be seen in the UK’s autumn vaccine booster campaign. Firstly, the majority of the population will no longer be eligible to receive the vaccine for free through the National Health Service and will have to pay for the vaccination themselves. The NHS is offering free vaccines to older people and clinically vulnerable people, but the vaccines available are designed for KP or even older virus variants.
The XEC variant, which is currently leading the new surge in infections, is expected to become predominant. It’s unclear exactly how effective current boosters are against it, but experience has shown that they are not as effective against the variants for which they were designed. The ability of the virus to mutate and evade protection from vaccines and previous infection means that COVID-19 will continue to spread unhindered through society after all major mitigation measures are lifted in March 2022. The fact that I have been forgiven has helped me tremendously.
Join the fight for socialism!
Once you fill out the form, your local WSWS representative will contact you about participating.
